1. ZHAW digitalcollection
  2. School of Management and Law
  3. Publikationen
  4. Publikationen School of Management and Law
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMattli, Renato-
dc.contributor.authorGrobet, Cécile-
dc.contributor.authorSharakin, Maxim-
dc.contributor.authorPöhlmann, Johannes-
dc.contributor.authorVinci, Linda-
dc.contributor.authorSyleouni, Maria-Eleni-
dc.contributor.authorCarlander, Maria-
dc.contributor.authorMeier, Flurina-
dc.contributor.authorEgli, Philipp-
dc.contributor.authorGerber-Grote, Andreas-
dc.contributor.authorWieser, Simon-
dc.date.accessioned2023-03-11T13:36:42Z-
dc.date.available2023-03-11T13:36:42Z-
dc.date.issued2022-
dc.identifier.urihttps://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/infliximab.htmlde_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/27287-
dc.description.abstractBackground: In Switzerland, relatively low biosimilar prescription rates have prompted the interest of the authorities. A health technology assessment (HTA) was requested to compare the available evidence of the infliximab reference product and its biosimilar for treating rheumatoid arthritis (RA). Objective: This HTA examines the efficacy, effectiveness and safety of the infliximab biosimilar compared to its reference product in RA and presents the health economic impact of a potentially increased biosimilar utilization in Switzerland. Furthermore, ethical, legal, social and organisational aspects of treatment initiation with biosimilars or switching to biosimilars are analysed. Research questions: Is it safe, efficacious and effective 1) to initiate treatment with infliximab biosimilar instead of the infliximab reference product, 2) to switch treatment from the infliximab reference product to infliximab biosimilar and 3) to switch treatment from infliximab biosimilar to the infliximab reference product in patients with RA? Methods: A systematic literature search for evidence on efficacy, effectiveness, safety and health economic outcomes of the infliximab reference product compared to biosimilars in RA was conducted. Meta-analysis was performed for outcomes with sufficient available evidence. The certainty of evidence for relevant outcomes was assessed by applying the GRADE approach. A de novo health economic model was built to assess cost differences between a RA patient treated with infliximab reference product and a patient treated with its biosimilar using a lifetime time horizon. The potential budget impact for Switzerland was estimated over the next five years. The health economic analysis focused on drug costs. Additional physician time and lab tests that may be required related to the switch were also considered. Furthermore, a targeted search for evidence on biosimilar-related ethical, legal, social and organisational aspects was conducted and findings were summarized and discussed. Results: We identified five randomized controlled trials (RCTs) which reported their results in nine publications, 17 real-world evidence (RWE) studies and 13 health economic studies. All included RCTs showed similar clinical efficacy and safety after treatment initiation with biosimilar compared to its reference product. The performed meta-analysis confirmed that there is no difference in efficacy and safety outcomes between treatment initiation with biosimilar and reference product. The certainty of evidence for the critical and important outcomes was judged as moderate to high. Two studies analysed switching from reference product to biosimilar compared to the continuation of reference product treatment. Both studies found comparable efficacy and safety outcomes (i.e. similar number and severity of adverse events) between the analysed groups. Their certainty of evidence was judged as low to moderate. None of the identified studies reported on switching from biosimilar to the reference product. A de novo cost-minimisation analysis showed that treatment initiation with infliximab reference product costs CHF 18’065 more per RA patient than treatment initiation with infliximab biosimilars over a lifetime time horizon. This cost difference is solely based on differences in drug costs. When considering uncertainty behind different model parameters, the difference in drug costs over a lifetime ranged between CHF 10’380 and CHF 23’342 per patient. The budget impact analysis assumed policy scenarios in which the price of the infliximab reference product would be decreased or the use of biosimilars promoted. Cost savings were estimated at CHF 1.58 million over 5 years for approximately 60 annual incident RA patients eligible for infliximab with a range between CHF 0.58 million and 4.78 million. Staying on the infliximab reference product costs CHF 17’812 more per patient than switching to the infliximab biosimilars over a lifetime time horizon (range: CHF 10’126 to CHF 23’088). This cost difference includes differences in drug costs as well as additional physician time and lab tests that may be required related to the switch. In the budget impact analysis savings related to switching to the biosimilar amounted to CHF 9.32 million over 5 years based on approximately 1’000 prevalent RA patients currently treated with the infliximab reference product. When considering uncertainty behind the eligible patient population and future treatment mix the budget impact ranged from CHF 2.20 million to CHF 17.30 million. There were no severe nor highly controversial ethical issues identified based on the scientific evidence concerning treatment initiation with infliximab reference product vs. infliximab biosimilars or when switching from the reference product to biosimilars of infliximab in patients with RA. From a legal perspective, interchangeability of biologics is a key issue. Interchangeability of biologics in Switzerland is not explicitly regulated by neither the therapeutic products law nor the health insurance law. Currently, the decision about interchangeability in an individual case rests with treating physicians in compliance with their professional duties and due diligence. No evidence on social issues associated with the use of biosimilars were identified. Organisational issues may relate to policies to (not) promote and (not) implement biosimilars nationwide. Within this context, relevant are the profit margins that depend on the price of a product. As reference products have higher prices compared to biosimilars, there are financial incentives to use reference products instead of biosimilars.de_CH
dc.format.extent199de_CH
dc.language.isoende_CH
dc.publisherBundesamt für Gesundheit BAGde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subject.ddc362.1041: Gesundheitsökonomiede_CH
dc.titleInfliximab reference product versus biosimilar for the treatment of rheumatoid arthritisde_CH
dc.typeWorking Paper – Gutachten – Studiede_CH
dcterms.typeTextde_CH
zhaw.departementGesundheitde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitWinterthurer Institut für Gesundheitsökonomie (WIG)de_CH
zhaw.publisher.placeBernde_CH
zhaw.funding.euNode_CH
zhaw.originated.zhawYesde_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
There are no files associated with this item.
Show simple item record
Mattli, R., Grobet, C., Sharakin, M., Pöhlmann, J., Vinci, L., Syleouni, M.-E., Carlander, M., Meier, F., Egli, P., Gerber-Grote, A., & Wieser, S. (2022). Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis. Bundesamt für Gesundheit BAG. https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/infliximab.html
Mattli, R. et al. (2022) Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis. Bern: Bundesamt für Gesundheit BAG. Available at: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/infliximab.html.
R. Mattli et al., “Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis,” Bundesamt für Gesundheit BAG, Bern, 2022. [Online]. Available: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/infliximab.html
MATTLI, Renato, Cécile GROBET, Maxim SHARAKIN, Johannes PÖHLMANN, Linda VINCI, Maria-Eleni SYLEOUNI, Maria CARLANDER, Flurina MEIER, Philipp EGLI, Andreas GERBER-GROTE und Simon WIESER, 2022. Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis [online]. Bern: Bundesamt für Gesundheit BAG. Verfügbar unter: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/infliximab.html
Mattli, Renato, Cécile Grobet, Maxim Sharakin, Johannes Pöhlmann, Linda Vinci, Maria-Eleni Syleouni, Maria Carlander, et al. 2022. “Infliximab Reference Product versus Biosimilar for the Treatment of Rheumatoid Arthritis.” Bern: Bundesamt für Gesundheit BAG. https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/infliximab.html.
Mattli, Renato, et al. Infliximab Reference Product versus Biosimilar for the Treatment of Rheumatoid Arthritis. Bundesamt für Gesundheit BAG, 2022, https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/infliximab.html.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.